Introduction: Low-density lipoprotein cholesterol (LDL-C) remains a well-established risk factor for cardiovascular disease (CVD). LDL-C levels are considered primary targets of therapy. A new series of 10 systemic biomolecules, the monoclonal antibodies (mAbs) of proprotein convertase subtilisin/kexin type 9 (PCSK9), have a higher activity in reducing LDL-C. Areas covered: The authors critically review the current evidence on the efficacy and safety of bococizumab, a humanized mAb against PCSK9, which was surprisingly discontinued in November 2016. The pharmacokinetic profile and the biological features of bococizumab vs others mAbs are also 15 discussed. As of now, in adjunct to diet, alirocumab and evolocumab are the only approved PCSK9 mAbs for the treatment of adult patients with severe clinical atherosclerotic CVD already at maximallytolerated statin therapy and require additional LDL-C lowering. Expert opinion: Although discontinued, data from a phase 2b trial show the effectiveness of bococizumab in lowering LDL-C in a similar way to the two available PCSK9 antagonists. However, some 20 peculiar biological characteristics of bococizumab may explain the attenuation of LDL-C lowering over time, as well as a higher rate of immunogenicity and of injection-site reactions.
Introduction
Hyperlipidemias, multifactorial conditions partly genetically and partly life habit induced, represent the most important under-25 lying risk factors for cardiovascular disease [1] . The primary effort in hypolipidemic drug therapy is focused on lowering the primary carriers of cholesterol, namely low-density lipoproteins (LDLs) [2] . Among drugs primarily reducing LDL -cholesterol (LDL-C), the monoclonal antibodies (mAbs) against 30 proprotein convertase subtilisin/kexin protein 9 (PCSK9), alirocumab and evolocumab, have been approved in the United States and in the European Union in August 2015 [3] . As of now, the best characterized activity of secreted PCSK9 is to post translationally regulate the number of cell-surface LDL receptors 35 (LDL-R) [4] . The PCSK9 gene, coded on chromosome 1p32.3, is ubiquitously expressed. It binds to the LDL-R, thus not allowing the uptake of LDL particles from extracellular milieu into cells [5] . By this mechanism, PCSK9 raises LDL-C levels.
In adjunct to diet, PCSK9 inhibitors are indicated for the 40 treatment of adult patients with severe clinical atherosclerotic cardiovascular disease (i.e. heart attacks or strokes), who are already at maximally tolerated statin therapy and requiring additional LDL-C lowering [6, 7] . The efficacy of PCSK9 inhibitors is dramatic and may reach up to 55% LDL-C lowering as 45 monotherapy [8] [9] [10] and up to 61% when added to standard therapy [11, 12] . Of note, the currently approved indications report that heterozygous familial hypercholesterolemic (HeFH) and homozygous familial hypercholesterolemic (HoFH) patients may be treated with evolocumab [13] , whereas alir-50 ocumab may be prescribed only to HeFH patients [14] .
Overview of current developments
Alongside with evolocumab (Repatha -Amgen
AQ3
) and alirocumab (Praluent -Sanofi and Regeneron Pharmaceuticals), [15] . In a statement issued on 1 November 2016, Pfizer surprisingly announced discontinuation of global development of bococizumab, its investigational PCSK9 mAb.
Furthermore, based on the data from these three compounds, data on the safety and efficacy of the novel agent RN317 (PF-05335810; Pfizer) have been reported from a Phase 1 randomized study. This humanized mAb is an engineered IgG2∆ that binds to PCSK9 with a lower affinity at low pH (acidic endosomal compartment) compared to neutral pH (plasma). The pH-sensitive binding to PCSK9 prolongs the entity of RN317 half-life extending the duration of LDL-C reduction over an 85-day dosing interval. RN317 appears to escape endosomal degradation and, thus, can be recycled and 70 potentially reutilized [16] .
Safety and efficacy data of LY3015014 (Lilly
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) have been reported in a Phase 2 study [17] . LGT209 (Novartis
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) has been discovered as a lipid lowering agent but licensed to another 75 (Roche/Genentech) was discontinued in 2014 [18] .
Another approach to a possible antagonism to PCSK9 may be by RNA interference (ALN-PCSSC -Alynam
AQ8
) [19] whose single-dose administration led to a rapid and dose-dependent reduction in plasma PCSK9 protein. Higher doses of ALN-PCS 80 resulted in more prolonged PCSK9 reduction [19] . The treatment was shown to be safe with similar adverse events between ALN-PCSsc and placebo groups [19] .
A similar interference may be obtained with a PCSK9 binding small molecule (Adnectin; Bristol-Myers Squibb R&D 85 Company),
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for which only animal data are available [20] . Finally, vaccination against PCSK9 represents a potential approach to reduce the administration to once a year injections; participants are being recruited to Phase 1 clinical trials of two vaccine candidates (ATH04A and ATH06A by AFFiRiS). Bococizumab is a humanized mAb against PCSK9; this feature makes it different from the other two mAbs anti-PCSK9, alirocumab and evolocumab, both are fully human antibodies. Although the incidence of immune reactions to mAbs is 105 usually limited (from <1% to 10%) [21] , the immunoreactivity potential decreases from the first generation of chimeric antibodies to the last series of fully human antibodies [22, 23] . Indeed, if compared with chimeric and humanized mAbs, they generally show reduced immunogenicity [24] . Anti-boco-110 cizumab antibodies were detected in approximately 7% of treated patients after 24 weeks of administration. One patient (0.4% of total) also developed a partial reduction of the hypocholesterolemic effect of bococizumab, suggesting a potential antagonized effect of endogenous antibodies developed dur-
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ing therapy by the immune system [25] .
The development of autoantibodies anti -mAbs has also been registered with both evolocumab and alirocumab, although with a lower incidence. In the DESCARTES AQ11 study, 2 out of 901 patients had detectable binding antibodies before 120 or at the time of randomization and 1 had transient antievolocumab-binding antibodies after 52 weeks of treatment [8] . No neutralizing antibodies were observed in any treated patient [8] . In the LAPLACE-2 In a pool of 10 placebo-and active-controlled trials, 4.8% of patients treated with alirocumab showed anti drug antibodies newly detected after initiating treatment, as compared to 0.6% of controls. In addition, 1.2% of patients developed neutralizing antibodies on at least one occasion and 0.3% exhibited transient or prolonged loss of efficacy [14] .
As such, bococizumab appears to be more immunogenic in comparison to alirocumab and evolocumab with higher inci-dence of developing anti drug antibodies with neutralizing activity. However, it must be taken into account that immunogenicity data are highly dependent on the sensitivity and specificity of the assay. Generally, two-site (bridging) assays and radioimmunoassay are the most common techniques to measure immunogenicity [27] . Thus, the lack of standardized methodologies to measure immunogenicity makes any comparative considerations meaningless [27] .
It should be noted that, in the case of the most frequently used monoclonals, i.e. for the treatment of rheumatoid arthritis, a very high prevalence of antimonoclonal antibodies has been reported [28] . Regarding adalimumab, up to 35% of patients develop circulating antibodies, and the effect of such response on the therapeutic efficacy is still controversial, with studies that show no effect [28] , and others reported that antidrug antibo-dies are significant predictors of no response [29] . Thus, it is conceivable to conclude that the inability to maintain longterm and durable cholesterol lowering of bococizumab may be not exclusively related to the development of anti drug antibodies, but other mechanisms could be envisioned.
A second consideration on the biochemical properties of bococizumab is related to its IgG isotype. Both bococizumab and evolocumab are IgG2-λ, whereas alirocumab is an IgG1. Although the pharmacological implications of these differences still need to be determined, Yoo et al. showed that 165 antibodies of the human IgG2 subclass can form covalent dimers in vivo and that IgG2 dimers occur in human serum 185 Thus, based on their innate roles in immune responses, Fcγ receptors may be involved in the clearance of alirocumab-PCSK9 complexes from cells opsonized by the mAb [33] . However, the significance of Fcγ receptor-mediated catabolism of mAbs is unclear [33] .
3. Pharmacodynamics
Bococizumab was selected across 800 mAbs from hybridoma cell lines, generated by fusing the spleen of wild-type and PCSK9 null mice immunized with human PCSK9 protein [34] . The antibodies that positively bound PCSK9 by an ELISA
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195 assay were then tested for their effect on the LDL -R degradation in the liver cell line Huh7 incubated with recombinant PCSK9 [34] . Screening led to the identification of four antibodies produced by the hybridoma, completely blocking the activity of PCSK9 on the LDL-R and one of them (J10) 200 showed approximate affinities of 0.3, 0.5, and 2.7 nM with recombinant human, cynomolgus monkey, and mouse PCSK9. J10 also completely and dose-dependently inhibited the binding of human PCSK9 to the LDL-R with an IC 50 of 1 nM [34] . J10 was then engineered into a human IgG2Δ A 205 and κ chain antibody for further improving its antigen-binding affinity. From these changes, the J16 antibody containing the fully human sequence AQ14 outside of the complementarity -determining regions was obtained. J16 binds to a recombinant human PCSK9 molecule with a Kd 210 of approximately 5 pM, a cynomolgus monkey PCSK9 with a Kd of less than 100 pM, and a mouse PCSK9 with a Kd of 35 pM. J16 completely blocks the human and mouse PCSK9 binding to the LDL-R [34] .
The co-crystal structure of the Fab region of J16 and recom-215 binant PCSK9 showed that the binding site is located mainly within the catalytic domain of PCSK9, involved in the interaction with the LDL-R. In particular, J16 binds the epitope that almost perfectly overlaps with the LDL-R EGF-A
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domain binding site on PCSK9 [35] . Both light and heavy chains mediate 
Pharmacokinetics and metabolism
The pharmacokinetic (PK) profile of bococizumab has been recently reported [16] . Bococizumab, when administered to hypercholesterolemic subjects on statin therapy as subcutaneous (s. 
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cantly shorter than those of evolocumab and alirocumab (11-17 and 17-20 days, respectively) [13, 14] .
As expected for a mAb, the steady -state volume of distribution (V ss ) of bococizumab is 17.6 l , i.e. a relatively small value, due to the limited capacity of mAbs to diffuse into different 240 tissues [22] . Absolute bioavailability for bococizumab 1.0 mg/ kg s.c., compared with bococizumab i.v. injection, is 12.5% [16] . Bioavailability is 44.6% for bococizumab (3.0 mg/kg) s.c. using dose-normalized AUC
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for i.v. (bococizumab 1.0 mg/kg) as the reference [16] .
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A PK/pharmacodynamic ( PD) model has been developed in order to characterize the relationship among bococizumab dose, plasma concentrations, and LDL-C response [37] . The data for this analysis were derived from a Phase 2b clinical trial [25] . A two-compartment PK model with parallel first-250 order and Michaelis-Menten kinetics was linked to an indirect response model describing LDL-C response. Clinical trial simulation indicated a robust reduction in LDL-C and even greater LDL-C lowering if no dose titration was implemented in the Phase 2b study [25] . This analysis clearly indicates that the PK 255 profile of bococizumab follows a two-compartment model with parallel first-order and Michaelis-Menten elimination. A similar PD profile between alirocumab, evolocumab, and bococizumab after the biweekly administration indicates a similar persistence of the antibodies in the circulation.
Although the PK interactions of mAbs and small-molecule drugs are limited, it is tempting to speculate that the clearance of bococizumab, similar to alirocumab and evolocumab, increases in the presence of the co administration of statins [13, 14] . Indeed, statins can induce PCSK9 expression facilitat-
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ing the cellular uptake and clearance of mAbs anti -PCSK9 by the cells [22] . This interaction was not considered clinically relevant for both alirocumab and evolocumab. No dose adjustment being required in the case of statin co administration [13, 14] . 
280 mean pain score of 3.82 ± 7.75 mm (visual analog scale ranging from no pain [0 ] to 100 mm) [38] .
NCT00991159 evaluated safety and tolerability of single, escalating, i.v. infusions to healthy adults. NCT01243151 evaluated the safety and tolerability of repeated doses in volun-285 teers with hypercholesterolemia. NCT01435382 estimated the absolute bioavailability of bococizumab in subjects with hypercholesterolemias, not on lipid-lowering therapy. NCT02043301 studied the single -dose PK of bococizumab after s.c. injection into the abdomen, upper arm, or thigh.
290 NCT02458209 assessed the s.c. PK and PD of bococizumab in healthy adults by comparing drug substances manufactured at two different locations and administration via prefilled syringe vs. prefilled pen. NCT01163851 evaluated the PK and PD of a single dose of bococizumab in volunteers on stable atorvasta-295 tin doses; the trial website reports the obtained data.
NCT01163838 was stopped prior to enrollment.
Phase 2 studies
Before publication of a full manuscript [25] , data on Phase 2a studies were presented in abstract forms; i.e. in 135 subjects 300 with a mean baseline LDL-C of 123 mg/dL, already at highdose statins (atorvatstain or simvastain 40 or 80 mg or rosuvastatin 20 or 40 mg), a 12 -week treatment with 3 and 6 mg/ kg of bococizumab, administered i.v. every 4 weeks, gave LDL-C reductions of 46% and 56% [38, 39] .
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The NCT01592240, a Phase 2 multicenter, double-blind, placebo-controlled, dose-ranging trial in 351 adults (299 completed treatment) with baseline fasting LDL ≥80 mg/dL and triglycerides ≤400 mg/dL, reported no CV AQ17 events within 6 months. Randomized subjects received every 14 days s.c. 310 placebo or bococizumab 50, 100, or 150 mg, alternatively every 28 days s.c. placebo or bococizumab 200 or 300 mg. The trial foresaw a peculiar dose-ranging design in which an LDL-C fall to ≤25 mg/dL corresponded to a reduction in bococizumab dose administration. The primary end point 315 was the absolute change in LDL-C from baseline to week 12 after randomization; 14 days bococizumab 150 mg (Q14) and bococizumab 300 mg (Q28) were the most effective doses. After placebo-adjustment, LDL-C and TC
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were significantly reduced by 53.4 mg/dL (Figure 1 ) and by 53.1 mg/dL (Q14) and by 44.9 mg/dL and by 45.6 mg/dL (Q28), respectively. Non-HDL-C AQ19 and apolipoprotein (apoB), further markers of CV risk, were significantly lowered by 55.6 and 32.1 mg/dL (Q14) and by 48.6 and 28.5 mg/dL (Q28), respectively. ApoB can be considered as equivalent to non-HDL-C especially in case of hypertriglycerid emias [2] . HDL-C levels were significantly raised by 6.5% (p = 0.043) in the Q28 arm. Regardless of doses, median percentage changes in TG
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showed a trend wise AQ21 to reduction. Median percentage reductions of Lp(a) were 9% and 10.7% at Q14 and Q28, respectively. ApoA-I increments were not statistically significant, 6.5% (Q14) and 2.7 (Q28). No differences were recorded for serious adverse AQ22 events across the placebo and bococizumab arms [25] . Nasopharyngitis and upper respiratory tract infections were found the most frequently adverse events with no differences between the pla-cebo and bococizumab arms; diarrhea, bronchitis, arthralgia, and injection-site reactions were the others. Seven patients (2%) discontinued treatment [25] .
Overall, the Q14 administration was more effective than the monthly one, and it has been applied to the Phase 3 studies.
Notably, after administration of bococizumab, a significant reduction of LDL-C was observed at week 2 with a gradual increase in the 2 -week post-nadir. Similar results were observed with evolocumab [40] and alirocumab [41] , suggesting similar clearance rates among mAbs.
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Phase 3 studies
These studies were halted after the company evaluation of the first results of a 52-week trial on the effects of bococizumab in lowering LDL-C. Pfizer announced the discontinuation of the late-stage PCSK9 inhibitor by a press release on 1 November The SPIRE program was planned to involve more than 30,000 participants worldwide, comprehensive of 6 lipid-low-ering studies and 2 cardiovascular outcome trials [43] . All of these trails were aimed at evaluating efficacy, safety, tolerability, magnitude of reduction in atherogenic lipids as well as reduction in the occurrence of major CV events, namely death due to CVD, myocardial infarction, stroke, and unstable angina requiring urgent revascularization [44] .
The following trials were designed to evaluate efficacy of 12-week treatment with bococizumab in lowering LDL-C (measured with a direct assay) . SPIRE-HR (NCT01968954) included 727 hyperlipidemic subjects (primary or mixed Figure 1 . Effect of bococizumab on mean absolute change from baseline in LDL-C following Q14 and Q28 days administrations. Reproduced by permission of Elsevier [25] . ated statin doses; SPIRE-LDL (NCT01968967) enrolled 2139 hyperlipidemic subjects (fasting LDL-C ≥70 mg/dL and triglyceride ≤400 mg/dL; high or very high risk of incurring a CV event) on highly effective dose statin; SPIRE-LL 375 (NCT01200514) enrolled 749 hyperlipidemic subjects, treated with a statin, with fasting LDL-C ≥100 mg/dL and triglyceride ≤400 mg/dL; SPIRE-AI (NCT02458287) enrolling 299 subjects with hyperlipidemia or dyslipidemia (fasting LDL-C ≥70 mg/dL and triglycerides ≤400 mg/dL; treated with a 380 statin) was aimed at evaluating the effect of bococizumab given by an auto-injector; SPIRE-FH (NCT01968980) included 370 HeFH patients.
Since LDL-C reduction, obtained with PCSK9 mAbs, has not been shown yet to reduce clinical CV outcomes, SPIRE-1 385 (NCT01975376) and SPIRE-2 (NCT01975389) were designed with CV events as their primary outcomes. The enrollment planned to follow about 28,000 high-risk subjects, both in primary and in secondary prevention, across a broad range of CV risk.
Expert opinion
390 Considering that LDL-C remains the well-established risk factor for CV disease, one of the main outcomes of the SPIRE program was to evaluate if the LDL-C reduction rate driven by bococizumab had some additional benefit among statin-treated and statin-intolerant patients, either in secondary prevention or in 395 high-risk primary prevention [43] . Indeed, the use of PCSK9 mAbs has been, very recently, recommended in (i) very highrisk patients, i.e. those requiring more than a 50% reduction in LDL-C despite already at maximally tolerated statin plus ezetimibe, (ii) in severe familial AQ23 hypercholesterolemia (FH) without 400 ASCVD, requiring a further LDL-C reduction, (iii) and in those, already belonging to above groups, who are statin intolerant [6] .
The overall evaluation of bococizumab for the management of hypercholesterolemia indicates an effective molecule with a similar activity as the two available PCSK9 405 antagonists, evolocumab and alirocumab, but with some differences in the type of selected mAb, i.e. being a humanized mAb. This characteristic may be linked to the occurrence of mAb antibodies, potentially leading to reduced effectiveness and occurrence of side effects. As pointed 410 out, in the case of mAbs for rheumatoid arthritis, occurrence of mAb antibodies is not necessarily linked to reduced effectiveness. This observation, therefore, may lead to a better understanding of the type of antibody selection to be carried out, in order to obtain the best cholesterol 415 response with the least immunogenicity. Pfizer could witness a clinical profile with an unanticipated attenuation of LDL-C lowering over time, as well as a higher level of immunogenicity and a higher rate of injection-site reactions with bococizumab than shown with the other agents in this safety profile of the two available PCSK9 antibodies, i.e. evolocumab and alirocumab, will require longer and more intensive monitoring. It is within this context that the FOURIER trial was designed to provide important safety data on the long-term administration of evolocumab and achievement of very low 435 LDL-C levels [45] . Particularly, neurocognitive effects of evolocumab are being assessed in the 'Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects (EBBINGHAUS)' trial (NCT02207634).
An interesting PD aspect of available PCSK9 antagonists is the lack of a reducing effect on the hs-C-reactive protein, a constant finding after statins [46, 47] . On the other hand, antibodies can markedly reduce the circulating levels of lipoprotein (a) [48, 49] , versus essentially no effect of statins. Although the mechanism of the reduction of Lp(a) observed during both alirocumab and evolocumab is unclear and debated, a recent finding has reported how PCSK9 does not significantly modulate Lp(a) catabolism, but can rather enhance the hepatic generation of Lp(a) [50] . Of note, Lp(a) reduction driven by bococizumab (−9% after 150 mg Q14) [25] was lower than that 450 observed with alirocumab (−19.5% after 150 mg Q14) [51] and evolocumab (−32.3% after 140 mg Q12), respectively
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[48]. Similar to statins [52] , the risk of new-onset diabetes is likely predictable with the use of PCSK9 inhibitors. Although randomized controlled trials with PCSK9 antagonists showed 455 no evidence of increased development of diabetes [53] , PCSK9 genetic variants, associated with lower LDL-C, positively correlated to an increased risk of type -2 diabetes mellitus [54] . A 19% higher risk for diabetes per 1-mmol/L reduction in LDL-C was acknowledged (1.19; 95% confidence interval , 1.02-1.38) [55] . Notably, the potentially increased risk of new-onset diabetes during treatment with a PCSK9 inhibitor is likely to be confined to subjects with impaired fasting glucose levels [56] .
Finally, the high cost of therapy with PCSK9 inhibitors for FH or atherosclerotic cardiovascular disease patients should be considered. Assuming that the 2015 prices of alirocumab and evolocumab are around $14,000 per year, the price should be reduced to $4 536 or less per patient to be cost-effective on total US healthcare spending [57] .
From the failure of the clinical development of bococizu-mab, one can potentially conclude that long-term treatment with PCSK9 inhibitors should be associated with a very low development of immunogenic mAbs. From available data, only fully human antibodies seem to be suitable for this therapy. Moreover, it should bear in mind that the s.c. injec-
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tion of mAbs in the presence of anti drug antibodies results in the local formation of immune complexes in the injection site, reducing the release of the drug into the circulation [27] . The development of pH -sensitive mAbs , such as RN317, appears to be a promising venue, also in view of the stability of response, apparently predicting a lower risk of events [16] . In addition, presently available data indicate that the ideal IgG isotype should be the IgG1, which is less prone to form dimers and to precipitate at the injection site. Unfortunately, the cost of these treatments remains one of the major limiting steps for use 485 in the general population. Development of classical small molecules with PCSK9-inhibitory activity appears to be more difficult, but probably an effective and less -expensive approach for generating a new class of hypocholesterolemic drugs. inhibitor therapy in patients with heterozygous familial hypercho-
